Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > ORGANIZATION
ORGANIZATION
- JPA to Bolster Strategies for Key Issues thru Policy Study Committee: Pres. Kodama
July 2, 2013
- JMA Sets Up Pharmaceutical Affairs Section
July 1, 2013
- Generic Share Reaches 25.8% by Volume, 10.5% by Price in FY2012: JGA
July 1, 2013
- JGA to Establish New Membership Category to Encourage Non-Member Companies to Provide Information through Its Website
June 27, 2013
- JGA Concerned about TPP Talks, Hopes Japan Will Adopt US Rules Favorable to Generic Makers
June 24, 2013
- JPMA Weighs Scheme to Allow Use of Clinical Research Evidence for Drug Applications
June 21, 2013
- Generic-Only Distributors Total 485, Only 17% Are Member Companies: Generic Distributor Association Survey
June 13, 2013
- FPMAJ Subcommittee Floats New Pricing Rule to Replace Cost Calculation Method
June 12, 2013
- FPMAJ Subcommittee Says NHI Prices of Essential Drugs Should Be Maintained; Stable Supply System for Disasters Envisioned as Requirement
June 11, 2013
- 30% of Newly Listed Drugs in FY2012 Developed at Request of Govt: FPMAJ Survey
June 10, 2013
- FPMAJ Committee Appoints Eisai’s Tsuchiya, Takeda’s Aoyagi as Vice Chairman
June 7, 2013
- Consumers Need to Take Caution with Online OTC Drug Sales: Keizai Doyukai Chairman Hasegawa
June 7, 2013
- Lifting of Ban on Online OTC Drug Sales Would “Create Situation of Grave Concern”: JMA Vice President Nakagawa
June 7, 2013
- Pros and Cons of Bungyo Should Be Reconsidered: JMARI Working Paper
June 6, 2013
- Sawai Gains Steady Market Shares of Generics in Broad Categories, Meiji Seika Pharma Strong in CNS: Survey
June 4, 2013
- ACCJ, EBC Advocate Preventive Health, Say Physicians Should Earn More by Keeping People Out of Hospitals
June 3, 2013
- Fewer Drug Makers Used Outside Organizations for MR Education and Training in FY2012: MREAC
June 3, 2013
- Drug Makers, R&D Organizations Sign Memorandum to Search Compounds for Infectious Disease Treatment: GHIT Fund
June 3, 2013
- JMA Demands Novartis Disclose Details of Internal Probe
May 31, 2013
- Actions Taken in 29 Prefectures to Eliminate Free Benefits and Labor Provided by Wholesalers: Industry FTC Reports
May 29, 2013
ページ
Japan’s health and finance ministers agreed late last year to go ahead with an “off-year” drug price revision in FY2027,…
The Japanese healthcare sector is experiencing rapid growth, demanding a highly skilled and diverse workforce. However, finding and attracting the best talent in this competitive market presents significant challenges.Enter AI. With the rise of AI-powered tools, healthcare organizations can revolutionize…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…